Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Debt (2022 - 2026)

TriSalus Life Sciences has reported Total Debt over the past 5 years, most recently at $33.1 million for Q1 2026.

  • For Q1 2026, Total Debt rose 4.35% year-over-year to $33.1 million; the TTM value through Mar 2026 reached $33.1 million, up 4.35%, while the annual FY2025 figure was $33.0 million, 49.64% up from the prior year.
  • Total Debt for Q1 2026 was $33.1 million at TriSalus Life Sciences, roughly flat from $33.0 million in the prior quarter.
  • Over five years, Total Debt peaked at $33.1 million in Q1 2026 and troughed at $2.5 million in Q4 2022.
  • A 5-year average of $22.3 million and a median of $22.1 million in 2024 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: skyrocketed 111.86% in 2024 and later increased 4.35% in 2026.
  • Year by year, Total Debt stood at $2.5 million in 2022, then surged by 309.75% to $10.0 million in 2023, then surged by 119.81% to $22.1 million in 2024, then soared by 49.64% to $33.0 million in 2025, then increased by 0.1% to $33.1 million in 2026.
  • Business Quant data shows Total Debt for TLSI at $33.1 million in Q1 2026, $33.0 million in Q4 2025, and $32.8 million in Q3 2025.